Skip to main content
Caplight Logo









inflamed pharma

inflamed pharma

Private
JenaHealthcare & Life Scienceshttps://inflamedpharma.com

Last Round

Grant

Mar 23, 2020

Company Overview

inflamed pharma operates in Healthcare & Life Sciences and is based in Jena. Its latest recorded funding round was a Grant round in March 2020.

inflamed pharma is a biotechnology company that provides a patented technology platform, JenCluTec®, to increase the water solubility and membrane permeability of small molecules.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical Imaging, Platform-as-a-Service

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

inflamed pharma Comparables

Compare inflamed pharma with similar companies based on industry and business-model similarity.

inflamed pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Zerion Pharma
86%
Harpago
82%
AustinPx
79%
Book a demo to see all comparables

For institutional investors. Book with your work email.

inflamed pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 23, 2020
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

inflamed pharma Investors

Notable investors and investment history

inflamed pharma investors
InvestorRounds
European Regional Development FundGrant
Xlife Sciences AGSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 23, 2020

    Received grant funding from the European Regional Development Fund.

Book a demo to see all signals

For institutional investors. Book with your work email.

inflamed pharma Filings

Explore SEC and related filing metadata, where available.

inflamed pharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about inflamed pharma's valuation, stock price, and market status.

Is inflamed pharma a public or private company?

inflamed pharma is a private company.

What is the current stock price of inflamed pharma?

inflamed pharma is a private company, so its shares have no public market price. Caplight tracks inflamed pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is inflamed pharma worth (valuation)?

Valuation information for inflamed pharma is not publicly available.

Can I buy inflamed pharma stock?

inflamed pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was inflamed pharma's last funding round?

inflamed pharma's most recent funding round was Grant on March 23, 2020.

Who are the main investors in inflamed pharma?

Key investors in inflamed pharma include Xlife Sciences AG.

Will inflamed pharma IPO soon?

No public IPO plans have been announced for inflamed pharma.

How can I track inflamed pharma secondary market activity?

Caplight tracks bids, offers, and trades in inflamed pharma's shares on secondary markets.

Firmographic Details

HeadquartersJena
Year Founded2016
Last FundingMar 23, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?